Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BETRF BetterLife Pharma	$0.07 -4.3%	$0.07	$0.05 ▼ $0.15	$8.55M	1.52	21,628 shs	1,555 shs
PULM Pulmatrix	$7.81 -2.1%	$6.79	$1.78 ▼ $10.40	$28.51M	1.45	133,230 shs	16,489 shs
RANI Rani Therapeutics	$0.53 -6.3%	$0.86	$0.46 ▼ $4.45	$30.20M	0.25	812,027 shs	303,264 shs
SXTC China SXT Pharmaceuticals	$1.83 -10.3%	$1.88	$0.95 ▼ $11.92	$28.97M	1.11	1.19 million shs	53,674 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BETRF BetterLife Pharma	-4.35%	+1.69%	-10.93%	-7.17%	-26.79%
PULM Pulmatrix	-4.09%	-10.34%	+24.69%	-5.67%	+320.00%
RANI Rani Therapeutics	-2.13%	+5.97%	+16.36%	-62.88%	-85.99%
SXTC China SXT Pharmaceuticals	+4.62%	+52.24%	+0.49%	-27.66%	-77.43%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BETRF BetterLife Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PULM Pulmatrix	0.4138 of 5 stars	0.0	3.0	0.0	0.0	3.3	0.0	0.0
RANI Rani Therapeutics	1.9269 of 5 stars	3.5	1.0	0.0	0.0	1.9	1.7	0.6
SXTC China SXT Pharmaceuticals	0.4832 of 5 stars	0.0	3.0	0.0	0.0	2.4	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BETRF BetterLife Pharma	0.00	N/A	N/A	N/A
PULM Pulmatrix	0.00	N/A	N/A	N/A
RANI Rani Therapeutics	3.00	Buy	$9.25	1,660.90% Upside
SXTC China SXT Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest BETRF, SXTC, PULM, and RANI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
5/16/2025	RANI Rani Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$14.00 ➝ $4.00
4/3/2025	RANI Rani Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00

(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BETRF BetterLife Pharma	N/A	N/A	N/A	N/A	($0.05) per share	N/A
PULM Pulmatrix	$1.92M	14.84	N/A	N/A	$4.93 per share	1.58
RANI Rani Therapeutics	$1.20M	25.16	N/A	N/A	$0.51 per share	1.03
SXTC China SXT Pharmaceuticals	$1.82M	15.93	N/A	N/A	$30.46 per share	0.06

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BETRF BetterLife Pharma	-$2.14M	-$0.02	N/A	∞	N/A	N/A	N/A	-999.57%	6/25/2025 (Estimated)
PULM Pulmatrix	-$14.12M	-$3.34	N/A	∞	N/A	-96.51%	-45.97%	-30.72%	8/11/2025 (Estimated)
RANI Rani Therapeutics	-$33.97M	-$0.99	N/A	N/A	N/A	N/A	-219.64%	-56.71%	8/5/2025 (Estimated)
SXTC China SXT Pharmaceuticals	-$3.10M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest BETRF, SXTC, PULM, and RANI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	PULM Pulmatrix	N/A	-$0.50	N/A	-$0.50	N/A	N/A
5/13/2025	Q1 2025	RANI Rani Therapeutics	-$0.22	-$0.22	N/A	-$0.22	N/A	$0.20 million
3/31/2025	Q4 2024	RANI Rani Therapeutics	-$0.24	-$0.27	-$0.03	-$0.27	N/A	$1.03 million
3/21/2025	Q4 2024	PULM Pulmatrix	N/A	-$0.54	N/A	-$0.54	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BETRF BetterLife Pharma	N/A	N/A	N/A	N/A	N/A
PULM Pulmatrix	N/A	N/A	N/A	N/A	N/A
RANI Rani Therapeutics	N/A	N/A	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BETRF BetterLife Pharma	N/A	0.05	0.05
PULM Pulmatrix	N/A	19.40	19.40
RANI Rani Therapeutics	2.34	1.60	1.60
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BETRF BetterLife Pharma	0.01%
PULM Pulmatrix	11.84%
RANI Rani Therapeutics	30.19%
SXTC China SXT Pharmaceuticals	5.02%

Insider Ownership

Company	Insider Ownership
BETRF BetterLife Pharma	34.77%
PULM Pulmatrix	0.62%
RANI Rani Therapeutics	50.42%
SXTC China SXT Pharmaceuticals	3.95%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BETRF BetterLife Pharma	7	129.46 million	84.45 million	Not Optionable
PULM Pulmatrix	20	3.65 million	3.63 million	Not Optionable
RANI Rani Therapeutics	110	57.48 million	26.75 million	Optionable
SXTC China SXT Pharmaceuticals	90	15.83 million	3.90 million	Not Optionable

BETRF, SXTC, PULM, and RANI Headlines

Recent News About These Companies

China SXT Pharmaceuticals Inc Ordinary Shares

April 23, 2025 | morningstar.com

China SXT Pharmaceuticals Reports Financial Results Amid Regulatory Challenges

March 28, 2025 | tipranks.com

China SXT Pharmaceuticals Optimizes Capital Structure with Warrant Exchange

March 19, 2025 | tipranks.com

China SXT Pharmaceuticals regains compliance with Nasdaq

March 17, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Has Regained Compliance with Nasdaq’s Minimum Bid Price Deficiency

March 17, 2025 | finance.yahoo.com

China SXT Pharmaceuticals Has Regained Compliance with Nasdaq's Minimum Bid Price Deficiency

March 17, 2025 | globenewswire.com

China SXT Pharmaceuticals Inc trading resumes

February 26, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Inc trading halted, volatility trading pause

February 26, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Inc trading halted, news pending

February 24, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Announces New Securities Purchase Agreement

January 27, 2025 | msn.com

China SXT Pharmaceuticals Inc (SXTC) Stock’s 0.02% Increase This Year: What’s the Story?

January 7, 2025 | bovnews.com

China SXT Pharmaceuticals Inc (SXTC) Stock Price Reaches $0.51: What Factors Are Influencing This Level?

January 1, 2025 | bovnews.com

China SXT Pharmaceuticals Inc (SXTC) Stock: Greater Than Its Current Valuation?

December 26, 2024 | bovnews.com

China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency

October 7, 2024 | globenewswire.com

china sxt pharmaceuticals - SXTC

October 3, 2024 | foxbusiness.com

China SXT Pharmaceuticals (NASDAQ:SXTC) Stock, Short Interest Report

October 2, 2024 | benzinga.com

Can China SXT Pharmaceuticals Inc (SXTC) Stock rise from its doldrums?

July 24, 2024 | bovnews.com

China SXT Pharmaceuticals Inc (SXTC) Stock creates opportunities due to its volume and complexity

May 21, 2024 | bovnews.com

JAGX, BSGM and SXTC among mid-day movers

April 16, 2024 | msn.com

China SXT Pharmaceuticals Inc.

February 23, 2024 | wsj.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BETRF, SXTC, PULM, and RANI Company Descriptions

BetterLife Pharma OTCMKTS:BETRF

$0.07 0.00 (-4.35%)

As of 06/12/2025 12:54 PM Eastern

BetterLife Pharma Inc., a biotechnology company, engages in the development and commercialization of compounds for the treatment of mental disorders in Canada. It is also involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections. The company's products pipeline includes BETR-001 for the treatment of major depressive disorder, anxiety, and neuropathic pain and other neuro-psychiatric and neurological disorders; and BETR-002 to treat benzodiazepine dependency, anxiety, and neurodegenerative disorders. It is also developing MM-003, which has completed Phase II clinical trials for treatment of COVID-19 and other respiratory viral infections; and MM-001, a topical cream for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia that has completed Phase II clinical trials. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.

Pulmatrix NASDAQ:PULM

$7.81 -0.17 (-2.13%)

Closing price 04:00 PM Eastern

Extended Trading

$7.80 -0.01 (-0.19%)

As of 04:04 PM Eastern

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.

Rani Therapeutics NASDAQ:RANI

$0.53 -0.04 (-6.28%)

Closing price 04:00 PM Eastern

Extended Trading

$0.53 +0.00 (+0.13%)

As of 04:28 PM Eastern

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

China SXT Pharmaceuticals NASDAQ:SXTC

$1.83 -0.21 (-10.29%)

Closing price 04:00 PM Eastern

Extended Trading

$1.84 +0.01 (+0.82%)

As of 04:16 PM Eastern

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time